Alkaline Phosphatase And Lactate Dehydrogenase In Pre-Eclampsia: A Case-Control Analysis

Abstract

Background: Pre-eclampsia is a serious hypertensive disorder that affects pregnant women and poses significant risks to maternal and fetal health. Early diagnosis and effective management of pre-eclampsia are essential for improving outcomes. This case-control analysis aimed to investigate the levels of Alkaline Phosphatase (ALP) and Lactate Dehydrogenase (LDH) in pre-eclampsia and compare them to a control group of pregnant women without pre-eclampsia.

Methods: A total of 200 pregnant women were enrolled in this study, with 100 diagnosed with pre-eclampsia as cases and 100 without pre-eclampsia as controls. Serum samples were collected, and ALP and LDH levels were measured using standard laboratory techniques. Statistical analyses, including t-tests and confidence interval calculations, were conducted to assess differences in ALP and LDH levels between the two groups.

Results: The results revealed significant differences in ALP and LDH levels between pre-eclampsia cases and controls. ALP levels were notably higher in the pre-eclampsia group compared to the control group (p < 0.001), suggesting potential placental involvement and liver dysfunction in pre-eclampsia. LDH levels were also significantly elevated in pre-eclampsia cases (p < 0.001), indicating potential tissue damage and endothelial dysfunction associated with the disorder.

Conclusion: This study provides evidence that both ALP and LDH levels are higher in cases of pre-eclampsia and lower in controls, suggesting their potential utility as diagnostic and prognostic markers for pre-eclampsia. These findings underscore the importance of monitoring these enzyme levels during pregnancy, especially in high-risk populations, to aid in early detection and timely intervention. Further research is warranted to validate these markers and explore their mechanistic roles in pre-eclampsia pathophysiology. Early diagnosis and management based on these markers could significantly improve outcomes for pregnant women and their infants affected by pre-eclampsia.